Market Overview

UPDATE: Canaccord Genuity Upgrades Intuitive Surgical; Sensitivity Analysis Suggests Upside

Share:
Related ISRG
Intuitive Surgical's Da Vinci Prostatectomy Bolus 'Has Legs,' Barclays Says
Intuitive Surgical Has 'Ample Runway' To Grow Despite Medtronic's Robotic Surgery Push, Canaccord Says

Canaccord Genuity upgraded Intuitive Surgical (NASDAQ: ISRG) from Hold to Buy and lowered the price target from $590.00 to $527.00.

Canaccord Genuity analyst Jason R. Mills commented, "Our valuation analysis for both scenarios uses 1) 1.5x P/E/G multiple (in line with mid/large cap med-tech comps), and 2) two-year EPS CAGR derived from the aforementioned scenarios. The “moderate” downside scenario generates a year-end '13 target of $517, while the “significant” downside scenario implies a $474 target. Averaging our previous target of $590 (based on current estimates) with these scenario-based targets gives us a mean year-end target of $527. With more than 10% upside potential to our new target (15% to be exact), we upgrade to a BUY rating."

Intuitive Surgical closed at $459.44 on Friday.

Latest Ratings for ISRG

DateFirmActionFromTo
Jun 2016Goldman SachsDowngradesBuyNeutral
Apr 2016Bank of AmericaMaintainsBuy
Apr 2016BTIG ResearchDowngradesBuyNeutral

View More Analyst Ratings for ISRG
View the Latest Analyst Ratings

Posted-In: Canaccord GenuityAnalyst Color Upgrades Analyst Ratings

 

Related Articles (ISRG)

View Comments and Join the Discussion!